Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Trial Details

NCT ID

NCT03618550

Phase

PHASE2

Sponsor

Memorial Sloan Kettering Cancer Center

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

• pembrolizumab
• gemcitabine
• vinorelbine
• liposomal doxorubicin
• Stem cell mobilization and collection
• Involved-site radiation therapy

Locations (sample)

• Duarte, California, United States|34.13945,-117.97729
• Stanford, California, United States|37.42411,-122.16608
• Miami, Florida, United States|25.77427,-80.19366
• Basking Ridge, New Jersey, United States|40.70621,-74.54932
• Middletown, New Jersey, United States|40.39428,-74.11709

Key Eligibility Criteria

• Histologic diagnosis of classical Hodgkin's lymphoma. Primary refractory or relapsed disease proven by biopsy at enrolling institution.
• Be willing and able to provide written informed consent/assent for the trial.
• Be ≥ 18 years of age on day of signing informed consent.
• PET scan before initiating pembro-GVD have measurable disease based on Lugano 2014 criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.